101
Participants
Start Date
December 17, 2020
Primary Completion Date
January 4, 2024
Study Completion Date
January 4, 2024
Nivolumab
Specified dose on specified days
Ipilimumab
Specified dose on specified days
Local Institution - 0007, New Delhi
Local Institution - 0017, Delhi
Local Institution - 0005, Ahmedabad
Local Institution - 0001, Mumbai
Local Institution - 0016, Mumbai
Local Institution - 0012, Pune
Local Institution - 0006, Bangalore
Local Institution - 0002, Karnataka
Local Institution - 0011, Trivandrum
Local Institution - 0019, Kolkata
Local Institution - 0013, Mumbai
Lead Sponsor
Bristol-Myers Squibb
INDUSTRY